


General Medical Clinics PLC
Sound Interim Results

32p

02 March 2010

Share Price: 32p



12m High: 32p

12m Low: 28.25p

Market Cap: £5.31m

Shares in Issue: 16.6m

NAV/Share: 18.4p (10.2p in cash)

Gearing: Nil

Interest Cover: N/A

EPIC Code: GMCP.PL

Sector: Healthcare

Market: London PLUS

Broker: Numis

Corporate Advisor: Axiom Capital

Website: www.genmed.org.uk

Description: Provider of Primary Care in the City and the West End including General Practice, physiotherapy, occupational health, health screening, nurse-led services, MASTA travel clinics, independent dentistry and visiting consultants.

Analyst: Yingheng Chen

Tel: +44(0)207 929 3399

Email: research@hardmanandco.com

Interim results for the period ended 30 November 2009 show:

- Good recovery in H1 trading, interim revenue of £3.6m, a 5% y-o-y increase. This includes a full six month sales from the Baker Street clinic. Gross profit was up 4.6% y-o-y, to £1.8m, indicating that GenMed has managed to maintain its margin even in a tough trading environment.
- EBITDA down by 32%, mainly due to continuing investment in the Baker Street clinic. On a comparative basis, i.e. taking out the £165k investment cost of Baker Street, EBITDA of £0.3m was up 46% compared to 1H08.
- Basic EPS was 0.1p, down from 0.7p in 1H08. On a comparative basis, basic EPS was up 65% to 1.12p, reflecting a much smaller tax charge.
- GenMed ends the six month period with £1.6m cash in the bank and no debt.
- GenMed has a track record of high contract renewal rates, i.e. over 95%. The group is also offering more services to its existing client base. The revenue per patient ratio increased over 11.6% to £78 on average.
- The group has also extended its agreement with MASTA for travel vaccinations for another three years.
- The group has started discussion with the Department of Health and NHS bodies concerning continuing its Liverpool Street NHS Walk-in Centre and the possibility of broadening the services offered.
- The Baker Street clinic is currently running at approx. 50% of its breakeven level. The group has appointed a new sales manager dedicated to exploring further opportunities in both the residential and corporate markets in this area. GenMed's management team continues to focus on achieving a cash neutral position for the Baker Street clinic as soon as possible.
- The Takeover Bid Approach. On 10 February, GenMed announced that it was approached by Westover Medical Ltd with a takeover proposal. The offer price of 34p cash per share is at an 84% premium to GenMed's NAV.

Hardman & Co is a connected advisor under the Takeover Code because it is contracted to write research on the company.

Y/E	Sales	Declared Profit	Adjusted Profit	Adjusted EPS (Basic)	P/E ratio	Divi	Yield
May	£m	£m	£m	p.		p.	%
2008A*	6.54	0.30	0.48	2.1	15.2	0.4	1.3
2009A**	6.61	0.12	0.36	1.7	18.8	0.5	1.6
2010E	Forecasts	Withdrawn.					
2011E	Forecasts	Withdrawn.					

* 2008 adjusted profit includes exceptional costs of £96,000.

** Adjusted figures in FY09 exclude the development costs incurred in the Baker Street Clinic.

General Medical Clinics

02 March 2010

Management	Major Shareholders																		
<p>Non-Executive Chairman: Harry Hyman</p> <p>CEO: Jerry Appleyard</p> <p>Company Secretary & Finance Director: Elliott Adams</p>	<table> <tr> <td>Directors holding*</td> <td>22.6%</td> </tr> <tr> <td>Lend Lease Property Corporation Limited*</td> <td>11.44%</td> </tr> <tr> <td>Smith & Williamson Nominees Limited</td> <td>5.32%</td> </tr> <tr> <td>Chelspire Limited</td> <td>4.97%</td> </tr> <tr> <td>Walbrook Trustees (Guernsey) Limited (Employee Share Option Trust)</td> <td>4.76%</td> </tr> <tr> <td>Watertown Investment Inc</td> <td>4.52%</td> </tr> <tr> <td>Mr L O Johnson</td> <td>4.43%</td> </tr> <tr> <td>Sir Peter Michael</td> <td>4.11%</td> </tr> <tr> <td>Barnard Nominees Limited – VCT1</td> <td>3.61%</td> </tr> </table>	Directors holding*	22.6%	Lend Lease Property Corporation Limited*	11.44%	Smith & Williamson Nominees Limited	5.32%	Chelspire Limited	4.97%	Walbrook Trustees (Guernsey) Limited (Employee Share Option Trust)	4.76%	Watertown Investment Inc	4.52%	Mr L O Johnson	4.43%	Sir Peter Michael	4.11%	Barnard Nominees Limited – VCT1	3.61%
Directors holding*	22.6%																		
Lend Lease Property Corporation Limited*	11.44%																		
Smith & Williamson Nominees Limited	5.32%																		
Chelspire Limited	4.97%																		
Walbrook Trustees (Guernsey) Limited (Employee Share Option Trust)	4.76%																		
Watertown Investment Inc	4.52%																		
Mr L O Johnson	4.43%																		
Sir Peter Michael	4.11%																		
Barnard Nominees Limited – VCT1	3.61%																		
Key Dates	Key Milestones																		
<p>AGM: 22 October 2009</p> <p>Next Interim Results: February 2010</p> <p>Next Full Year Results: October 2010</p>	<p>2004: Acquisition of Finsbury Healthcare</p> <p>2005: October – Signing of contracts with Department of Health for the Liverpool Street NHS Walk-in centre December – Opening of Liverpool Street NHS Walk-in centre</p> <p>2006: November – Successful completion of Private Placement Memorandum raising £1.5m December – Flotation on PLUS Markets</p> <p>2007: November – completion of capital re-organisation Opening of Canary Wharf clinic</p> <p>2008: Opening of Chancery Lane clinic</p> <p>2009: Opening of Baker Street Clinic</p>																		

* Include duplication.

General Medical Clinics

02 March 2010

Disclaimer

The conclusions and opinions expressed in the investment research accurately reflect the views of the first named analyst. Hardman & Co provides professional independent research services and the companies researched pay a set fee in order for this research to be made available. While the information in the research is believed to be correct, this cannot be guaranteed. There are no other conflicts of interest.

Neither Hardman & Co nor the analysts responsible for this research own shares in the companies analysed in this research note. Neither do they hold any other securities or derivatives (including options and warrants) in the companies concerned. Hardman & Co does not transact corporate finance and therefore does not earn corporate finance fees. It does not buy or sell shares, and does not undertake investment business either in the UK or elsewhere.

Hardman & Co does not make recommendations. Accordingly we do not publish records of our past recommendations. Where a Fair Value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price.

Our research is issued in good faith but without legal responsibility and is subject to change or withdrawal without notice. Members of the professional investment community are encouraged to contact the analyst concerned.

This research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated individuals. In the UK, any such individual who comes into possession of this research should consult their properly authorized professional adviser, or undertake one of the 'self certified' sophisticated investor tests that are available.

This research is not an offer to buy or sell any security.

Past performance is not necessarily a guide to the future and the price of shares, and the income derived from them, may fall as well as rise and the amount realised may be less than the original sum invested. For AIM and PLUS shares, it is the opinion of the regulator that risks are higher. Furthermore the marketability of these shares is often restricted.

This document must not be accessed or used in any way that would be illegal in any jurisdiction.

In some cases research is only issued electronically and in some cases printed research will be received by those on our distribution lists later than those receiving research electronically.

The report may be reproduced either whole or in part on condition that attribution is given to Hardman & Co, and on condition that Hardman & Co accepts no liability whatsoever for the actions of third parties in this respect.

Hardman & Co is not regulated by the Financial Services Authority (FSA).

© Hardman & Co.

Hardman & Co

4-5 Castle Court
London
EC3V 9DL
United Kingdom

Tel: +44(0)20 7929 3399
Fax: +44(0)20 7929 3377

www.hardmanandco.com

